The rapid diagnosis of Mycoplasma pneumonia using in situ hybridization on clinical samples.

Abstract

The microbiological etiology of seasonal upper respiratory illnesses in the United States is dominated by viruses, including influenza A, B, respiratory syncytial virus, and SARS-CoV2. Mycoplasma pneumonia, treatable with antibiotics, can also cause upper respiratory symptoms and is typically associated with about 15 % of cases. There is no clinical or radiologic finding diagnostic of Mycoplasma pneumonia infection and PCR-based testing is not routinely used in the clinical setting. Further, the bacteria grows slowly in culture and the diagnostic IgM response will take days after the onset of infection. Thus, a rapid diagnostic test for Mycobacterium pneumonia infection is needed. This study documented two cases of Mycoplasma pneumonia infection of the upper respiratory system using in situ hybridization in a series of over 20 patients who were being tested for SARS-CoV2 infection. The respiratory secretions were placed on a glass slide, fixed in 10 % buffered formalin, and then tested using a Mycoplasma pneumonia probe. The high bacterial number associated with acute infection allowed for straightforward detection by in situ hybridization in a few hours. Antibiotic therapy led to rapid resolution of the symptoms. This highlights the ability of standard in situ hybridization as a rapid diagnostic test for Mycoplasma pneumonia in the clinical setting.

• Authors: Gerard J Nuovo
• Journal: Annals of diagnostic pathology (Ann Diagn Pathol) Vol. 63 Pg. 152100 (Apr 2023) ISSN: 1532-8198 [Electronic] United States
• PMID: 36608457 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• RNA, Viral

Topics

• Humans
• Pneumonia, Mycoplasma (diagnosis, drug therapy, microbiology)
• RNA, Viral
• COVID-19
• SARS-CoV-2
• In Situ Hybridization
• COVID-19 Testing